赖诺普利联合氯沙坦钾治疗慢性心力衰竭的临床观察

Clinical observation of lisinopril combined with losartan potassium in the treatment of chronic heart failure

目的探讨氯沙坦钾、赖诺普利治疗慢性心力衰竭的临床疗效。方法选取我院2015年12月至2017年1月收治的88例慢性心力衰竭患者作为研究对象,将其分为对照组与研究组,各44例。对照组在常规治疗基础上加用赖诺普利,研究组在常规治疗基础上加用赖诺普利、氯沙坦钾。两组患者均连续治疗2个月,观察其临床疗效(治疗前、后心功能指标及心脏结构变化情况)与药物相关不良反应发生率。结果治疗后,两组LVEDD、LVESD、LVEF、心胸比率均改善,且研究组优于对照组(P<0.05);研究组不良反应总发生率为15.91%,与对照组的11.36%比较,差异不显著(P>0.05)。结论赖诺普利联合氯沙坦钾治疗慢性心力衰竭的效果显著,有利于保障患者生活质量,安全性高。

Objective To investigate the clinical efficacy of losartan potassium and lisinopril in the treatment of chronic heart failure. Methods Eighty-eight patients with chronic heart failure admitted in our hospital from December 2015 to January 2017 were selected as study subjects and divided into control group and study group, with 44 cases in each group.The control group was treated with lisinopril on the basis of routine treatment, while the study group was treated with lisinopril and losartan potassium on the basis of routine treatment. Both groups were treated for 2 months, the clinical efficacy（cardiac function and cardiac structural before and after treatment） and drug-related adverse reactions were compared in the two groups. Results After treatment, LVEDD, LVESD, LVEF and cardiothoracic ratio of both groups improved, and those of the study group were better than the control group（P〈0.05）. The total incidence of adverse reactions in the study group was 15.91%, compared with 11.36% in the control group, the difference was not significant（P〉0.05）. Conclusion Lisinopril combined with losartan potassium in the treatment of chronic heart failure has significant effect, which is conducive to ensuring the quality of life of patients, with high safety.